A Phase 3 Multicenter Randomized Double-Blind Parallel Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis

Brief description of study

The purpose of this research is to study mirikizumab, an investigational drug, developed as a potential treatment for Ulcerative Colitis (UC). The study includes a 12 week treatment period in which you will receive either study drug or placebo by IV infusion. A placebo has no medicine. You will receive one infusion every 4 weeks for approximately 30 minutes each. “Investigational” means that the drug being tested has not been approved for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). Before the treatment period is over you may be given a chance to continue treatments by participating in a maintenance study testing the same study drug. Participants will have two endoscopies throughout this study.

Clinical Study Identifier: s18-00080
ClinicalTrials.gov Identifier: NCT03518086

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.